CHANGES IN BODY-COMPOSITION OF CHILDREN WITH CHRONIC-RENAL-FAILURE DURING GROWTH-HORMONE TREATMENT

被引：12

作者：

VAISMAN, N

ZADIK, Z

DUCHAN, R

VOET, H

LOTAN, D

DRUKKER, A

机构：

[1] KAPLAN HOSP,PAEDIAT ENDOCRINE UNIT,IL-76100 REHOVOT,ISRAEL

[2] SOREQ NUCL RES CTR,IL-70600 YAVNE,ISRAEL

[3] FAC AGR REHOVOT,REHOVOT,ISRAEL

[4] NEPHROL UNIT,JERUSALEM,ISRAEL

来源：

PEDIATRIC NEPHROLOGY | 1994年 / 8卷 / 02期

关键词：

GROWTH HORMONE; CHRONIC RENAL FAILURE; BODY COMPOSITION;

D O I：

10.1007/BF00865478

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Growth hormone (GH) has different known metabolic effects, among which are lipolysis and anabolic action. We have studied the changes in body composition of children with chronic renal failure (CRF) after 1 year of daily treatment with GH. Body fat percentage and fat body mass (FBM) were derived from four site skinfold measurements; lean body mass (LBM) from total body potassium (TBK) and mid-arm muscle circumference (MAMC); bone mineral density (BMD) was measured by dual photon absorptiometry. GH treatment had a positive effect on weight, height and MAMC, but no effect on LBM (as reflected by TBK), FBM and BMD. Z-scores were derived in order to compare subjects with a normal population. While no significant change in z-score was noticed for weight, height, MAMC, FBM and BMD, TBK decreased during treatment. We conclude that GH therapy does not ultimately increase LBM in CRF patients compared with other GH-treated groups.

引用

页码：201 / 204

页数：4

共 20 条

[1]

Vaisman N., Zadik Z., Shamai Y., Changes in body composition of patients with subnormal spontaneous secretion of growth hormone, during the first year of treatment with growth hormone, Metabolism, 41, pp. 483-486, (1992)

[2]

Rees L., Rigden S.P.A., Ward G.M., Chronic renal failure and growth, Arch Dis Child, 64, pp. 573-577, (1989)

[3]

El-Bishti M., Burke J., Gill D., Jones R.W., Counahan R., Chantler C., Body composition in children on regular hemodialysis, Clin Nephrol, 15, pp. 53-60, (1981)

[4]

Hokken-Koelega A.C.S., Stijnen T., de Muinck Keizer-Schrama S.M.P.F., Et al., Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure, Lancet, 338, pp. 585-590, (1991)

[5]

Lippe B.M., Fine R.N., Koch V.H., Sherman M., Accelerated growth following treatment of children with chronic renal failure with recombinant human growth hormone (Somatrem), Acta Paediatr Scand, 343, pp. 127-131, (1988)

[6]

Tonshoff B., Mehls O., Heinrich U., Blum W.F., Ranke M., Schauer A., Growth-stimulating effects of recombinant human growth hormone in children with end-stage renal disease, J Pediatr, 116, pp. 561-566, (1990)

[7]

Moore D.J., Durie P.R., Forstner G.G., Pencharz P.B., The assessment of nutritional status in children, Nutr Res, 5, pp. 797-799, (1985)

[8]

Durnin J.V., Rahaman M.M., The assessment of the amount of fat in the human body from measurements of skinfold thickness, Br J Nutr, 21, pp. 681-689, (1967)

[9]

Frisancho A.R., New norms of upper limb fat and muscle areas for assessment of nutritional status, Am J Clin Nutr, 34, pp. 2540-2545, (1981)

[10]

Reba R.C., Cheek D.B., Leitnaker F.C., Body potassium and lean body mass, Human growth, (1968)

← 1 2 →